Sun Pharma, Aurobindo get US-FDA nod for anti-depressant tablets

摘要

Sun Pharmaceutical said its subsidiary has received approval for its Abbreviated, New Drug Application (ANDA) from the US-FDA to market bupropion hydrochloride antidepressants tablets. The US-based subsidiary of the company has received approval to market its bupropion hydrochloride extended-release tablets, Sun said in a press note. These tablets are available in strengths of 100 mg, 150 mg and 200 mg. Bupropion hydrochloride extended-release tablets are used for the treatment of major depressive disorder. These tablets are generic equivalent of GlaxoSmithKline's 'Wellbutrin SR' tablets.